T-705 (favipiravir) inhibition of arenavirus replication in cell culture

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 2, 2011, Pages 782-787

  Mendenhall, Michelle ^a   Russell, Andrew ^a   Juelich, Terry ^b   Messina, Emily L ^c   Smee, Donald F ^a   Freiberg, Alexander N ^b   Holbrook, Michael R ^b,f   Furuta, Yousuke ^d   De La Torre, Juan Carlos ^e   Nunberg, Jack H ^c   Gowen, Brian B ^a  

^a UTAH STATE UNIVERSITY   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF MONTANA   (United States)

^d TOYAMA CHEMICAL CO LTD   (Japan)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAVIPIRAVIR; NUCLEOSIDE; PURINE; RIBAVIRIN; RNA POLYMERASE; VIRUS RNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARENAVIRUS; ARTICLE; CELL ACTIVITY; CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; VIRUS RELEASE; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; ARENAVIRUSES, NEW WORLD; CELL LINE; CERCOPITHECUS AETHIOPS; HUMANS; JUNIN VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICROBIAL SENSITIVITY TESTS; PYRAZINES; RIBAVIRIN; VERO CELLS; VIRUS REPLICATION;

EID: 78751692774     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01219-10     Document Type: Article

References (29)

1. Bloom, J. D., L. I. Gong, and D. Baltimore. 2010. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328:1272-1275.
2. Borio, L., et al. 2002. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 287:2391-2405.
3. Chapman, L. E., et al. 1999. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir. Ther. 4:211-219.
4. Enria, D. A., A. M. Briggiler, and Z. Sanchez. 2008. Treatment of Argentine hemorrhagic fever. Antiviral Res. 78:132-139.
5. Flatz, L., A. Bergthaler, J. C. de la Torre, and D. D. Pinschewer. 2006. Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. Proc. Natl. Acad. Sci. U. S. A. 103:4663-4668.
6. Furuta, Y., et al. 2002. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 46:977-981.
7. Furuta, Y., et al. 2005. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49:981-986.
8. Furuta, Y., et al. 2009. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 82:95-102.
9. Geisbert, T. W., and P. B. Jahrling. 2004. Exotic emerging viral diseases: progress and challenges. Nat. Med. 10:S110-S121.
10. Gowen, B. B., et al. 2008. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One 3:e3725.
11. Gowen, B. B., et al. 2007. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother. 51: 3168-3176.
12. Gowen, B. B., et al. 2010. Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. Antiviral Res. 86:121-127.
13. Julander, J. G., K. Shafer, D. F. Smee, J. D. Morrey, and Y. Furuta. 2009. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob. Agents Chemother. 53:202-209.
14. Reference deleted.
15. Khan, S. H., et al. 2008. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res. 78:103-115.
16. Kiso, M., et al. 2010. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc. Natl. Acad. Sci. U. S. A. 107:882-887.
17. Lee, K. J., I. S. Novella, M. N. Teng, M. B. Oldstone, and J. C. de La Torre. 2000. NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. J. Virol. 74:3470-3477.
18. Lee, K. J., M. Perez, D. D. Pinschewer, and J. C. de la Torre. 2002. Identification of the lymphocytic choriomeningitis virus (LCMV) proteins required to rescue LCMV RNA analogs into LCMV-like particles. J. Virol. 76:6393-6397.
19. Morrey, J. D., et al. 2008. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res. 80:377-379.
20. NIAID (ed.). 2002. The counter-bioterrorism research agenda of the National Institute of Allergy and Infectious Diseases (NIAID) for CDC category A agents. NIAID, Bethesda, MD.
21. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. (Lond.) 27:493-497.
22. Rusnak, J. M., et al. 2009. Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea. Antiviral Res. 81:68-76.
23. Sánchez, A. B., and J. C. de la Torre. 2006. Rescue of the prototypic arenavirus LCMV entirely from plasmid. Virology 350:370-380.
24. Sidwell, R. W., et al. 2007. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob. Agents Chemother. 51:845-851.
25. Sleeman, K., et al. 2010. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob. Agents Chemother. 54:2517-2524.
26. Smee, D. F., et al. 2009. Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J. Antimicrob. Chemother. 64:741-746.
27. Snell, N. J. 2001. Ribavirin - current status of a broad spectrum antiviral agent. Expert Opin. Pharmacother. 2:1317-1324.
28. Streeter, D. G., et al. 1973. Mechanism of action of 1-β-D- ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. U. S. A. 70:1174-1178.
29. Weber, G., H. Nakamura, Y. Natsumeda, T. Szekeres, and M. Nagai. 1992. Regulation of GTP biosynthesis. Adv. Enzyme Regul. 32:57-69.